Supplementary Table 1. Baseline characteristics of male (n=249) and female (n=359) PsA patients treated with SEC.

PsA Features	MALE	vs. FEMALE	*p*
Male sex (N,%)	249 (100%)	0 (0%)	*NA*
Age (years), mean (SD)	51.45 (11.21)	53.70 (11.34)	*ns*
Age of diagnosis (years), mean (SD)	43.09 (10.84)	45.87 (11.82)	*ns*
Age of disease onset (years), mean (SD)	40.12 (13.02)	43.25 (13.96)	*ns*
Disease duration (years), mean (SD)	9.92 (7.08)	9.20 (6.68)	*ns*
PsA (n,%)	**249 (40.95%)**	**359 (59.05%)**	*NA*
Polyarticular	138 (55.42%)	225 (62.67%)	*ns*
Mono/Oligoarticular	74 (29.72%)	89 (24.79%)	*ns*
Axial	68 (27.31%)	78 (21.73%)	*ns*
Only involvement DIP	3 (1.20%)	6 (1.67%)	*ns*
Mutilating arthritis	0 (0%)	3 (0.83%)	*ns*
Enthesitis	117 (46.99%)	147 (40.95%)	*ns*
Dactylitis	52 (20.88%)	45 (12.53%)	*0.05*
Psoriasis, N (%)	186 (74.70%)	232 (64.62%)	*0.05*
Age of psoriasis onset (years), mean (SD)	24.12 (18.32)	23.24 (20.77)	*ns*
Onychopathy, N (%)	99 (39.76%)	123 (34.26%)	*ns*
IBD, N (%)	7 (2.81%)	4 (1.11%)	*ns*
Uveitis, N (%)	7 (2.81%)	18 (5.01%)	*ns*
Familiarity with psoriasis or PsA	89 (35.74%)	95 (26.46%)	*ns*
Erosions, N (%)	76 (30.52%)	98 (27.30%)	*ns*
Weight (kg), mean (SD)	81.08 (12.68)	68.59 (15.08)	*0.02*
Height (cm), mean (SD)	174.31 (7.04)	161.43 (13.91)	*0.04*
BMI, mean (SD)	26.58 (3.64)	25.91 (6.05)	*ns*
TJ [0-68], mean (SD)	6.17 (5.23)	9.30 (7.47)	*0.05*
SJ [0-66], mean (SD)	2.18 (2.45)	2.29 (3.05)	*ns*
LEI [0-6], mean (SD)	2.34 (1.61)	2.82 (1.95)	*ns*
Dactylitis [0-20] number digit, mean (SD)	0.23 (0.82)	0.31 (1.51)	*ns*
PASI [0-72], mean (SD)	4.96 (7.29)	3.70 (7.42)	*0.05*
ESR [0-25](mm/h), mean (SD)	18.99 (18.67)	22.59 (15.76)	*0.04*
CRP [0-6](mg/L), mean (SD)	7.54 (12.10)	5.70 (7.79)	*ns*
DAPSA [0-164], mean (SD)	23.77 (11.73)	26.35 (10.60)	*ns*
ASDAS [0-6], mean (SD)	3.04 (0.89)	3.44 (3.76)	*ns*
HAQ-S [0-8], mean (SD)	1.09 (0.67)	1.42 (0.91)	*ns*
VAS-pain [0-10], mean (SD)	6.50 (1.78)	6.84 (1.56)	*ns*
VAS-gh [0-10], mean (SD)	6.56 (1.54)	6.84 (4.44)	*ns*
BASDAI [0-10], mean (SD)	5.18 (2.17)	5.25 (2.19)	*ns*
BASFI [0-10], mean (SD)	5.16 (2.27)	5.19 (2.05)	*ns*
Mean treatment duration (months), mean (SD)	19.48 (10.88)	18.27 (11.40)	*ns*
Dosage 300 mg/injection (N,%)	136 (54.62%)	196 (54.60%)	*ns*
Dosage 150 mg/injection (N,%)	113 (45.38%)	163 (45.40%)	*ns*
1st line (N,%)	96 (38.55%)	131 (36.49%)	*ns*
Failure biological drugs (N,%)	153 (61.45%)	228 (63.51%)	*ns*
2nd line (N,%)	59 (23.69%)	90 (25.07%)	*ns*

3rd line (N,%)	50 (20.08%)	64 (17.83%)	*ns*
4th line (N,%)	29 (11.65%)	46 (12.81%)	*ns*
5th line (N,%)	12 (4.82%)	14 (3.90%)	*ns*
6th line (N,%) or more	5 (2.01%)	14 (3.90%)	*ns*
Concomitant NSAIDs, N (%)	121 (48.59%)	193 (53.76%)	*ns*
Concomitant steroid, N (%)	66 (26.51%)	96 (26.74%)	*ns*
Concomitant csDMARDs, N (%)	92 (36.95%)	164 (45.68%)	*ns*
Methotrexate	72 (28.92%)	130 (36.21%)	*ns*
Sulphasalazine	9 (3.61%)	36 (10.03%)	*0.05*
Leflunomide	11 (4.42%)	15 (4.18%)	*ns*
Hydroxychloroquine	5 (2.01%)	4 (1.11%)	*ns*
cyclosporine	2 (0.80%)	5 (1.39%)	*ns*

Legend: Data are expressed as mean (standard deviation=SD) unless otherwise specified; range of possible values are indicated in square brackets.

$p \leq 0.05$. Values were computed by means of a chi-square test (for proportion) or Wilcoxon's test (for continuous data).

PsA, psoriatic arthritis; DIP, distal interphalangeal joints; IBD, inflammatory bowel disease; PASI, Psoriasis Area Severity Index; TJ,Tender Joint; SJ, Swollen Joint; LEI, Leeds Enthesitis Index; DAPSA, Disease Activity Index for Psoriatic Arthritis; Kg, kilogram; cm, centimeter; BMI, body mass index; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; ASDAS, Ankylosing Spondylitis disease activity score; HAQ-S, Health Assessment Questionnaire modified for spondyloarthritis; NSAIDS, non -steroidal inflammatory drugs; csDMARDs, conventional synthetic disease modifying antirheumatic drugs. ns=not statistically significant. NA= not applicable